Research Article

Time to Develop and Predictors for Incidence of Tuberculosis among Children Receiving Antiretroviral Therapy

Fassikaw Kebede,* 1 Tsehay Kebede ,2 Birhanu Kebede, 3 Abebe Abate, 4 Dube Jara, * 4 Belete Negese 5 and Tamrat Shaweno 6

1Woldia University, College of Health Science, School of Public Health, Department of Epidemiology & Biostatics, Ethiopia 2021 2Bahir Dare University, Faculty of Social Science, Department of Geography & Environmental Studies, Ethiopia 2021 3Pawe Woreda Agricultural Inpute and Production Team Leaders, Metekel Zone, Pawe Woreda, North West, Ethiopia 4Debre Markos University, College of Medicine and Health Sciences, Department of Public Health 2021, Debre Markose, Ethiopia 5Debre Birhan University, College of Medicine and Health Sciences, Department of Nursing 2021, Debre Birhan, Ethiopia 6Jimma University Institute of Health Science, Faculty of Public Health, Department of Epidemiology 2021, Jimma, Ethiopia

Correspondence should be addressed to Fassikaw Kebede; fassikawk@yahoo.com

Received 8 January 2021; Revised 16 September 2021; Accepted 27 October 2021; Published 13 November 2021

Academic Editor: Karl Drlica

Copyright © 2021 Fassikaw Kebede et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Infection by the human immune deficiency virus (HIV) is the strongest risk factor for latent or new infection of tuberculosis (TB) through reduction of CD4 T-lymphocytes and cellular immune function [1]. The coinfections of TB/HIV are bidirectional, and the diseases reinforce each other, in that HIV sustains the progression of latent tuberculosis bacilli into active TB, while tuberculosis accelerates the progression of HIV disease to its advanced clinical stage [1, 2]. In 2019, there were an estimated 10.1 million new cases of TB and 1.7 million new deaths, making TB the leading cause of death from a single infectious agent (ranking above HIV/AIDS) [3]. In fact TB is responsible for one–third of TB/HIV-associated deaths for children living with HIV [4, 5]. The burden of this

1. Introduction

The human immune deficiency virus (HIV) is the strongest risk factor for latent or new infection of tuberculosis (TB) through reduction of CD4 T-lymphocytes and cellular immune function [1]. The coinfections of TB/HIV are bidirectional, and the diseases reinforce each other, in that HIV sustains the progression of latent tuberculosis bacilli into active TB, while tuberculosis accelerates the progression of HIV disease to its advanced clinical stage [1, 2]. In 2019, there were an estimated 10.1 million new cases of TB and 1.7 million new deaths, making TB the leading cause of death from a single infectious agent (ranking above HIV/AIDS) [3]. In fact TB is responsible for one–third of TB/HIV-associated deaths for children living with HIV [4, 5]. The burden of this
disease is higher in sub-Saharan Africa, where HIV remains a significant problem with inadequate coverage with antiretroviral drugs [6]. Globally, about 36.7 million people were living with HIV/AIDS, and 2.1 million people became newly infected in 2015. The sub-Saharan Africa countries account for the largest proportion, with 25.6 million people living with HIV [1, 3]. Likewise, in 2018, there were about 251,000 deaths from TB among PLWHIV, which accounts for 33% of total deaths associated with HIV, which is much higher than the case fatality rate expected by WHO, which is ≤5% [1, 7]. Despite different interventions, TB incidence rate in children on ART is high in different settings at different times. Notably, 0.28 per 100 person-years reported in Latin America [8], 1.9 per 100 person-years reported in Zambia [9], 4.0 and 21.1 per 100 person years in South Africa [10], and 17.4 in East Africa [11]. Often in resource-limited settings, estimates of TB in children have been based on extrapolation from adult data [4], but children with TB differ significantly from adult TB patients in their immunological and pathophysiological responses [7].

The Ethiopian Federal HIV and AIDS Prevention and Control Office estimated that the single national HIV/AIDS is among the top ten high burden counties with an incidence rate of 341/100,000 of which 31% of TB patients are living with HIV [5, 7]. Still now, TB/HIV coinfection is the leading cause of death in people living with HIV/AIDS [12]. Although the incidence of TB among adult HIV patients has been exhaustively studied, it is overlooked for HIV-positive children receiving antiretroviral therapy. So, this study was intended to determine the incidence rate and predictors for the time to developed TB among HIV-positive children receiving antiretroviral therapy in North West, Ethiopia 2021.

2. Methods

2.1. Study Design, Area, and Populations. Facility-based retrospective cohort study was employed among 421 seropositive children from 1st January 2011 to December 31/2020 in two (Assosa and Pawe) general hospitals. Both are located in the Benishangul Gumuz region, Northwest of Ethiopia [13]. Apart from other services, these hospitals have been providing ART follow-up care services since 2007. In the hospital, the recorded number of HIV-positive people starting ART care was 2968, of who were 447 HIV-positive children files were there since January 1, 2011 and December 31, 2020 (Figure 1).

2.2. Sample Size Determination and Sampling Techniques. The sample size was calculated by using the formula for survival analysis by [14] considering two-sided significance level (α = 5%), \( Z_{\alpha/2} = Z \) value at 95%confidence interval = 1.96, power (\( Z_{\beta} = 80 \%), and \( P \) = cumulative occurrence of TB incidence, 1.65 HR [15].

The final sample size \( n = \frac{\text{Event}}{P(\text{Event})} \cdot \frac{(Z_{\alpha/2} + Z_{\beta})^2}{\theta^2} = \frac{(z_{\alpha/2} + Z_{\beta})^2}{p(1-p)(\ln(\text{HR}))^2} \),

\[ \theta = \ln(\text{HR}), \]

\[ \text{HR} = \theta^e, \] (1)

where alpha is (\( \alpha \)) = 0.05, beta is (\( \beta \)) = 0.2, AHR is the hazard ratio, E is the number of event, and N is the (sample size) = \( E/P(E) \), where \( P(E) = \) probability of event, and \( P \) is the cumulative occurrence of treatment failure using values from reference for sample size calculation from two [16]. The final sample size was determined as 430 after adding 10% contingency for incompleteness. From 1st January 2011 to December 31/2020 in the two general hospitals, 447 children started ART care. We included all without any sampling procedure.

Exclusion criteria: patients taking anti-TB treatment at the time of HIV/AIDS enrolment were excluded from the study.

2.3. Outcome Ascertainment. The new incidence of TB considered as an event of interest, which is defined as the occurrence of TB in HIV-positive children during successive follow-up at any time after enrollment in the pediatrics HIV care clinic. Children who were lost, died, transferred out, or did not develop the events until the last visit were considered censored, whereas variables including sociodemographic such as age, sex, residence, family size, parental history of TB contact, plus clinical factors like WHO clinical stage, baseline cluster of differentiation (CD4 count), High, functional status, and nutritional status like (stunting, wasting, underweight, MUAC) were considered as independent variables.

2.4. Operational Words. Smear-positive pulmonary tuberculosis: at least one sputum smear examination is positive for acid fast bacilli (AFB) by direct microscopy. Smear-negative pulmonary tuberculosis: sputum specimens negative for AFB and radiographical abnormalities were consistent with active TB and the decision by a clinician to treat with a full course of antituberculosis chemotherapy. Extra Pulmonary TB: defined as tuberculosis outside the lung usually results from hematogenous dissemination. Sometimes infection directly extends from an adjacent organ. Symptoms vary by site but generally include fever, malaise, and weight loss. Diagnosis is most often by sputum smear and culture and, increasingly, by rapid molecular-based diagnostic test. Serpositive children: children who had human immune deficiency virus (HIV) in their blood and catgories under age less than 15 years.

2.5. Data Collection Instruments and Quality Assurance. A structured English version checklist was developed and used for data extraction from the patients’ medical records sheet and Federal Ministry of Health Pediatrics antiretroviral therapy (ART) follow-up form [17]. Four diploma nurses and two degree nurses were recruited for data collection and supervision. One day of training was given for data collection and supervision procedures. A pretest was conducted on 5% of the final sample size at Felege Selam health center to check the reliability of the checklist. After the pretest, necessary modification of the data collection tool was made. Strict follow-up and supervision were carried out during data collection by the principal investigators, and feedback was given daily.

2.6. Data Processing and Analysis. EPI-DATA version 3.2 and STATA/14 software were used for data entry and analysis, respectively. Proportional hazard assumption was checked for each variable, and no variable was found with
Schoenfeld residual test < 0.05. Categorical variables at bivariable Cox regression were assessed for candidates transferred at P value < 0.25 for final multivariable Cox regression models, and variables associated with TB incidence in 95% CI at P < 0.005 were claimed as the predictor.

2.7. Ethical Approval and Consent of Participants. Ethical clearance and ethical approval were obtained from the research institute review board (IRB) of Debre Markose University with reference (Refall no: DMU IRB-984/118/13). A formal letter was submitted to all three hospitals for permission to be done. Debra Markose University waived consent from caregivers in addition to the national research, and ethical review guide waived consent for secondary files.

3. Results

3.1. Baseline Sociodemographic and Clinical Characteristics. After excluding 11 individuals' files due to incompleteness, we reviewed a total of 421 charts registered from 1st January 2011 to December 31, 2020 as depicted (Figure 1). The mean (± SD) age of study participant was 10.6 ± 3.3 years. More than three-fifths of 261 (62%) participant children were aged ≥11 years, and the majority 219 (52%) of them were from the rural area. About 57.5% of participant had both parents (Table 1).

3.2. Baseline Clinical, Hematological, and Laboratory Characteristics. Of the total, 128 (30%) and 89 (21%) of participant children were found to be in clinical world health organization stages (WHO) I and III, respectively. Nearly more than three-fifths of 261 (62%) participant children were aged ≥11 years, and the majority 219 (52%) of them were from the rural area. About 57.5% of participant had both parents (Table 1).

3.3. Baseline Nutritional Status of HIV-Infected Children. Of the total, 33 (8%) and 72 (17%) cases had severe stunting and moderate wasting, respectively. However, 303 (72.3%) participants were on normal percentiles of weight for age > −2 Z-score (Table 2).

3.4. Time to Developed Tuberculosis. In this study, a total of 421 study participants were followed for a different period, contributing a cohort of 1043.1 PY of observation with minimum and maximum of observation 4 to 98 months.

During the follow-up period, 64 (15.2%) individuals were developed new tuberculosis. This makes the overall incidence density rate(IDR) participant children was found 5.9 (95% CI: 4.7; 7.7) per 100 person-years of risk observation. Majority, 44 (70%), of new cases occurred after ART that started 3 years later. About 44 (69%) cases were EPTB, and the remaining 19 (30%) were PTB (Table 3).

At the end of follow-up, 357 (85%) participant children were censored (excluded), among these 199 (47%) were on follow-up, 91 (21.6%) transferred into adult cohort, and 12 (4.7%) cases died (Figure 2).

3.5. Kaplan Meier TB Free Probability. The median duration of TB-free probability time was found 35 (IQR = ±29) months. The mean TB-free survival time of the entire follow up was 74.5 months (95% CI: 73.8, 84.3 months). Tuberculosis-free survival probability by the end of the follow-up was determined as 28.5% (95% CI; 22.3-36.9%) (Figures 3–5).

3.6. Predictors for Tuberculosis Incidence. In the final multi-Variabel Cox regression model, only three variables found respectively. Thirty nine percent of the children had an opportunistic infection. Bacterial pneumonia 53 (35.9%) and PCP 27 (21.6%) were the commonest. Of the total, 147 (35%) had hemoglobin ≤ 10 mg/dl, and more than two-thirds 276 (66%) children vaccinations. Majority, 338 (80%), of cases were in the appropriate developmental stage, while 56 (13.4%) children had poor ART adherence (Table 1).
Table 1: Baseline sociodemographic, clinical, and laboratory characteristics of children received ART in two public hospitals (between = 2009 and 2018).

| Variables                  | Categories               | Numbers (total = 421) | Percent |
|----------------------------|--------------------------|------------------------|---------|
| Sex                        | Male                     | 204                    | 49      |
|                            | Female                   | 217                    | 51      |
| Age                        | ≤5 years                 | 46                     | 11      |
|                            | Between 6 and 10         | 114                    | 27      |
|                            | ≥11 years                | 261                    | 62      |
| Residence                  | Urban                    | 205                    | 48      |
|                            | Rural                    | 216                    | 51      |
| Family size                | ≤2                       | 133                    | 31      |
|                            | 3-4                      | 219                    | 52      |
|                            | 5-6                      | 50                     | 11      |
|                            | ≥7                       | 19                     | 5       |
| Hemoglobin                 | >10 mg/dl                | 263                    | 63      |
|                            | ≤10 mg/dl                | 158                    | 38      |
| WHO                        | Stage I                  | 128                    | 30      |
|                            | Stage II                 | 147                    | 35      |
|                            | Stage III                | 89                     | 21      |
|                            | Stage IV                 | 57                     | 13      |
| CD4 count                  | <100                     | 30                     | 7       |
|                            | 101-200                  | 74                     | 7       |
|                            | ≥201                     | 317                    | 75      |
| Functional status          | Working                  | 307                    | 72      |
|                            | Ambulatory               | 72                     | 17      |
|                            | Bedridden                | 42                     | 10      |
| Adherence                  | Good                     | 224                    | 59      |
|                            | Fair                     | 121                    | 29      |
|                            | Poor                     | 56                     | 13      |
| Isoniazid                  | Took                     | 258                    | 61      |
|                            | Missed                   | 163                    | 38      |
| Cocotrimoxazole            | Took                     | 321                    | 76      |
|                            | Missed                   | 100                    | 23      |
| Opportunistic infections   | Present                  | 126                    | 29      |
|                            | Absent                   | 295                    | 70      |
| Vaccination                | Completed                | 276                    | 66      |
|                            | Not updated              | 76                     | 18      |
|                            | Defaulted                | 69                     | 16      |
| TB contact history         | Yes                      | 135                    | 32      |
|                            | No                       | 286                    | 68      |
| Change of AR regiment      | Present                  | 85                     | 20      |
|                            | Absent                   | 336                    | 79      |
| Parental status            | Both parent alive        | 242                    | 57      |
|                            | Paternal orphan          | 115                    | 27      |
|                            | Maternal orphan          | 38                     | 9       |
|                            | Both parent orphan       | 26                     | 6       |
significantly associated with time to developed TB. Of this, the risks of developing TB for children who were not taking cotrimoxazole preventive therapy (CPT) were nearly three times higher as compared participant children who took CPT (AHR = 2.5: 95% CI, 1.84-4.74, P < 0.021). Likewise, the risks of acquiring TB infection for seropositive children being nutritionally curve (height for age (HFA) ≤ −3 Z score) or being severely stunted were three times (AHR = 2.9: 95% CI, 1.2-7.8, P < 0.03) higher than as compared with participant children having normal percentiles (HFA, > −2 Z score).

Hemoglobin levels had a high predictive value for incident TB; indeed, baseline hemoglobin ≤ 10 mg/dl was four times increase the hazard of developing TB as compared to children having ≥ 10 mg/dl (AHR = 4.02: 95% CI, 2.1-8.1, P < 0.001) (Table 4).

### 4. Discussion

This study is aimed at assessing TB incidence rate and its predictors in children on ART. Accordingly, at the end of

---

**Table 2:** Baseline nutritional status of seropositive children attending HIV/AIDS care in two public hospitals North West Ethiopia 2021 (N = 421).

| Nutritional parameter                  | Frequency | Percent | chi²(2) | P < 0.05 |
|----------------------------------------|-----------|---------|---------|----------|
| Weight for height (WFH) normal (>−2 Z score) | 304       | 72      |         |          |
| Moderate wasting ≤ −2 − 3 Z score      | 71        | 17      | 7.5724  | 0.023    |
| Severe wasting ≤ −3 Z score            | 46        | 11      |         |          |
| Height for age (HFA) normal (>−2 Z score) | 284       | 68      |         |          |
| Moderate stunting ≤ −2 − 3 Z score     | 104       | 5       | 5.9262  | 0.052    |
| Severe stunting ≤ −3 Z score           | 33        | 8       |         |          |
| Weight for age(WFA) normal (>−2 Z score) | 277       | 66      |         |          |
| Moderate underweight ≤ −2 − 3 Z score  | 115       | 27      | 9.1780  | 0.010    |
| Severe underweight ≤ −3 Z score        | 29        | 7       |         |          |

**Table 3:** Time to developed TB incidence for seropositive children attending HIV/AIDS care in public hospitals between January 2011 and December 31/2020, North West Ethiopia (N = 421).

| Years | No. of children at started | Withdrawn during year | At risk children | No. of TB case (63) | TB incidence | Cumulative probability | Survival rate | 95% CI |
|-------|---------------------------|-----------------------|------------------|---------------------|--------------|------------------------|--------------|-------|
| >1 year | 421 (100)               | 13 (20.6)             | 408 (96.9%)   | 13 (20.6)         | 13 (3.1%)    | 13 (20.6%)             | 96.7%        | 94.5-98.1 |
| 2 years | 408 (96.9%)             | 18 (28.5%)            | 390 (92.6%)   | 18 (28.5%)        | 18 (4.3%)    | 31 (49.2%)             | 90.5%        | 86.5-93.2 |
| 3 years | 390 (92.6%)             | 8 (12.6%)             | 382 (90.7%)   | 8 (12.6%)         | 8 (1.9%)     | 39 (61.8%)             | 86.3%        | 81.5-89.9 |
| 4 years | 382 (90.7%)             | 5 (7.93%)             | 377 (89.5%)   | 5 (7.93%)         | 5 (1.15%)    | 44 (69.7%)             | 82.5%        | 76.5-87.1 |
| 5 years | 377 (89.5%)             | 12 (19.0%)            | 365 (86.6%)   | 12 (19.0%)        | 12 (2.8%)    | 56 (88.7%)             | 61.9%        | 49.5-72.8 |
| 6 years | 365 (86.6%)             | 4 (6.34%)             | 361 (85.7%)   | 4 (6.34%)         | 4 (0.98%)    | 60 (95.1%)             | 38.9%        | 29.1-57.5 |
| 7 years | 361 (85.7%)             | 2 (3.17%)             | 359 (85.2%)   | 2 (3.17%)         | 2 (0.047%)   | 62 (98.2%)             | 29.9%        | 26.5-46.4 |
| End of follow | 358 (84.8%)         | 1 (1.72%)             | 358 (84.8%)   | 1 (1.72%)         | 1 (0.023%)   | 63 (100)               | 28.5%        | 22.3-36.9 |
| Total | 63 (100)                | —                     | 63 (100)      | —                   | 100          | —                      | —            | —     |

**Figure 2:** Seropositive children started HIV/AIDS care status in two public hospitals during data collection in public January 2011 to December 31/2020, North West Ethiopia (N = 421).
the study period, 63 (15%) participants developed new TB incidence, making the overall incidence density rate 5.9 cases per 100 person-years (95% CI: 4.68; 7.68). This is higher than reported from Southern Ethiopia 2.6/100 PYs [18], Debre Markos 2.63/100 PYs [19], Northern Ethiopia 4.2/100 PYs [16], and Gonder 4.9/100 PYOs [20] but lower than findings in Adama hospitals 6.03/100 PYs [21] and South Africa 21.1/100 PYO [10]. This difference might be due to the higher burden of tuberculosis in resource-limited settings [1]. HIV was the immune system and acceleration viral replication responsible depletion of CD4 count [7] and associated
with precipitation of new episode for opportunistic infections. This can be reduced early by addressing CPT and IPT, which are inexpensive and highly effective for reducing loads of endogenous reactivation of latent TB [22]. However, being seropositive children who missed CPT were significantly associated with risks of developed TB incidence. This finding is comparable with those reported in Gonder hospital [16] and Adam hospital [20]. The finding of this research also indicated that HIV-infected children having severe stunting were independently associated with the incidence of TB as compared with HIV-infected children who have no stunting. This is in line with the finding in Adama [21], Tanzania [23], Uganda, and Zimbabwe [9]. This might be due to HIV infection increasing nutrient malabsorption due to metabolic alterations that culminate in weight loss and stunting with time leading to early exposure for opportunistic infections [24]. Similarly, the existence of rapid viral replication consumed body energy and creates an arena for the incidence of TB [25, 26]. This finding also showed that children having hemoglobin ≤ 10 mg/dl were independently associated with TB incidence as compared with HIV-infected children having hemoglobin levels > 10 mg/dl. This is in line with the study finding in Adama hospital [21], Gonder hospital [20], Northern Ethiopia [16], Dar es Salaam, Tanzania [23], and England [27]. In fact, this is due to hemoglobin levels having a high predictive value for incident TB and death. TB incidence is directly associated with severe anemia [28]. Regardless of ART, moderate or severe anemia during ART follow-up can be an independent predictor for TB [28, 29].

4.1. Limitation of the Study. The retrospective nature of this study is one of the limitations of this study. Due to this, some of the clinically important predictor variables that have been independently associated with the incidence of TB occurrence in other studies, like the educational status of children and economic status of the family, were not included in this study.

5. Conclusion

Tuberculosis incidence was high among seropositive children attending HIV/AIDS care, especially in the first three years after ART initiated as compared with that of subsequent years, since more than half of 44 (69%) new cases of TB occurred. Levels of hemoglobin, missed cotrimoxazole preventive therapy, and nutritionally severe stunting (HFA = ≤ −3 Z score) were significantly associated with the incidence of tuberculosis. Besides, intensified screening for provisions of isoniazid preventive therapy to children living with HIV/AIDS is highly recommended.
Abbreviations

HIV: Human immune deficiency syndrome
TB: Tuberculosis
AHR: Adjusted hazard ratio
PLWHIV: People living with HIV
WFH: Weight for height
WFA: Weight for age
HFA: Height for age
PYO: Person years of observations
LLH: Log likely hood ratio.

Data Availability

The data of this original research are available from the corresponding author upon reasonable request.

Consent

There is no consent for this study.

Disclosure

In the role the funders took in the study, funders had no role in this study as I am a Ph.D. candidate in the abovementioned university, and funders have no role except giving their students on the time of research.

Conflicts of Interest

All authors declare that they have no competing interest in this research.

Authors’ Contributions

FK, TG, and TK were equally contributing to the work reported, conception, study design, execution, analysis, and interpretation and writing the manuscript, and finally, all authors approved for submission.

Acknowledgments

Our final heartfelt thanks goes to Tamirate Shewan (Assistant Professor of Epidemiology), for his unreserved cleaning, editing, and rewriting of this manuscript for final submission. This study material and financial support are from Debre Markose University’s Post-Graduate School as a Ph.D. student research support fund.

References

[1] FMOH, Ethiopia-National guidelines for TB, DR-TB and Leprosy in Ethiopia—Sixth Edition, 2017.
[2] K. A. Alene, K. Viney, H. C. Moore, M. Wagaw, and A. C. A. Clements, "Spatial patterns of tuberculosis and HIV co-infection in Ethiopia,” PLoS One, vol. 14, no. 12, article e0226127, 2019.
[3] WHO, GLOBAL TUBERCULOSIS REPORT 2020, 2020.
[4] WHO, GLOBAL TUBERCULOSIS REPORT 2019, 2019.
[5] Z. Dawit, S. Abebe, S. Dessu, M. Mesele, S. Sahile, and D. Ajema, "Incidence and predictors of mortality among children co-infected with tuberculosis and human immunodeficiency virus at public hospitals in Southern Ethiopia,” PLoS ONE, vol. 16, no. 6, article e0253449, 2021.
[6] A. Alemu, A. Yesuf, B. Zerihun, M. Getu, T. Worku, and Z. W. Bitew, "Incidence and determinants of tuberculosis among HIV-positive individuals in Addis Ababa, Ethiopia: A retrospective cohort study,” International Journal of Infectious Disease, vol. 95, no. 95, pp. 59–66, 2020.
[7] FMOH, NATIONAL CONSOLIDATED GUIDELINES FOR COMPREHENSIVE HIV PREVENTION, CARE AND TREATMENT. Manuel, Accesed, September 2021, 2018.
[8] K. R. Ravichandra, B. R. Praharaj, and S. Agarwalla, "Opportunistic infections in HIV infected children and its correlation with CD4 count,” International Journal of Contemporary Pediatrics, vol. 4, no. 5, pp. 1743–1747, 2012.
[9] And The ARROW Trial Team, A. Crook, A. Turkova et al., “Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy,” BMC Medicine, vol. 14, no. 1, pp. 2–11, 2016.
[10] N. A. Martinson, H. Moultrie, R. Van Niekerk et al., “HAART and Risk of tuberculosis in HIV-infected South African children: a multi-site retrospective cohort study,” International Journal of Tuberc and Lung Disuberc Lung Diseas, vol. 13, no. 7, pp. 862–867, 2009.
[11] A. Ciarranello, Z. Lu, S. Ayaya et al., “Incidence of World Health Organization stage 3 and 4 events, tuberculosis and mortality in untreated, HIV-infected children enrolling in care before 1 year of Age,” The Pediatric Infectious Disease Journal, vol. 33, no. 6, pp. 623–629, 2014.
[12] F. Kebede, B. Kebede, T. Kebede, and M. Agmasu, “Effect of isoniazid preventive therapy on the incidence of tuberculosis among seropositive children attending HIV/AIDS care in two general hospitals, Northwest Ethiopia, 2021,” Journal of Tropical Medicine, vol. 2021, Article ID 9996953, 9 pages, 2021.
[13] F. Kebede, N. Eticha, B. Negese, M. Giza, T. Tolossa, and B. Wakuma, “Predictors for a cure rate of severe acute malnutrition 6-59 month children in stabilizing center at Pawe General Hospital, Northwest Ethiopia: retrospective cohort study,” International Journal of Child Health and Nutrition, vol. 10, no. 1, pp. 34–43, 2021.
[14] M. T. Beshir, A. H. Beyene, K. G. Tlaye, and T. M. Demelew, “Incidence and predictors of tuberculosis among HIV-positive children at Adama Referral Hospital and Medical College, Oromia, Ethiopia: a retrospective follow-up study,” Epidemiology and Health, vol. 41, article e2019028, 2019.
[15] D. F. Moore and D. F. Moore, Applied survival analysis using R. Piscataway, Springer Nature, NJ, USA, 2015.
[16] D. F. Moore, and D. F. Moore, Applied survival analysis using R. Piscataway, Springer Nature, NJ, USA, 2015.
[17] FMOH, Ethiopian Federal democratic republic of Ethiopia: Ministry of Health National consolidated guidelines for comprehensive HIV prevention, care and treatment, 2014, https://aidsfree.usaid.gov/sites/default/files/ethiopia_natl_gl_2014.pdf/14.
[18] K. D. Yirdaw, D. Jerene, Z. Gasu et al., "Beneficial effect of isoniazid preventive therapy and antiretroviral therapy on the incidence of tuberculosis in people living with HIV in Ethiopia,” PLoS ONE, vol. 9, no. 8, article e104557, 2014.
[19] N. Eahet, “Incidence of tuberculosis in children on antiretroviral therapy: a retrospective cohort study,” *BMC Research Notes*, vol. 11, 2018.

[20] S. G. Ayalaw, K. A. Alene, and A. A. Adane, “Incidence and predictors of tuberculosis among HIV positive children at University of Gondar Referral Hospital, Northwest Ethiopia: a retrospective follow-up study,” *vol. 2015, Article ID 307810, pp. 1–6, 2015.*

[21] M. T. Beshir, A. H. Beyene, K. G. Tlaye, and T. M. Demelew, “Incidence and predictors of tuberculosis among HIV-positive children at Adama Referral Hospital and Medical College, Oromia, Ethiopia: a retrospective follow-up study,” *Epidemiology and Health*, vol. 41, article e2019028, 2019.

[22] N. Gopalan, P. Chandrasekaran, S. Swaminathan, and S. Tripathy, “Current trends and intricacies in the management of HIV-associated pulmonary tuberculosis,” *AIDS Research and Therapy*, vol. 13, no. 1, p. 34, 2016.

[23] N. Li, K. P. Manji, D. Spiegelman et al., “Incident tuberculosis and risk factors among HIV-infected children in Tanzania,” *Aids*, vol. 27, no. 8, pp. 1273–1281, 2013.

[24] FMOH, *National Guidelines for Comprehensive HIV Prevention, CARE AND TREATMENT. GUIDELINE*, 2017.

[25] J. O. Alarcón, L. Freimanis-Hance, M. Krauss et al., “Opportunistic and other infections in HIV-infected children in Latin America compared to a similar cohort in the United States,” *Aids Research and Human Retroviruses*, vol. 28, no. 3, pp. 282–288, 2012.

[26] World Health Organizations, *Antiretroviral therapy for HIV infection in infants and children: towards universal access*, WHO Library Cataloguing-in-Publication Data, 2010.

[27] A. T. Brennen, R. Bonawitz, K. Schnippel et al., “Incident tuberculosis in HIV-positive children, adolescents and adults on antiretroviral therapy in South Africa,” *The International Journal of Tuberculosis and Lung Disease*, vol. 20, no. 8, pp. 1040–1045, 2016.

[28] A. Mocroft, O. Kirk, S. E. Barton et al., “Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe,” *Aids*, vol. 13, no. 8, pp. 943–950, 1999.

[29] A. D. Kerkhoff, R. Wood, F. G. Cobelens, A. Gupta-Wright, L. G. Bekker, and S. D. Lawn, “The predictive value of current haemoglobin levels for incident tuberculosis and/or mortality during long-term antiretroviral therapy in South Africa: a cohort study,” *BMC Medicine*, vol. 13, no. 1, p. 70, 2015.